Advanced Urothelial Carcinoma
Advanced Urothelial Carcinoma
Advertisement
Zachary BessetteAdvanced Urothelial Carcinoma | September 22, 2023
The phase 3 KEYNOTE-A39/EV-302 study has met its dual primary end points of OS and PFS in advanced or metastatic UC.
Read More
Ivan de Kouchkovsky, MDAdvanced Urothelial Carcinoma | September 19, 2023
Dr. de Kouchkovsky highlights survival and response rates after ICIs and EV for patients with squamous histology.
Ivan de Kouchkovsky, MDAdvanced Urothelial Carcinoma | September 19, 2023
Dr. de Kouchkovsky explains studying the impact of squamous histology on clinical outcomes in mUC after ICIs or EV.
Emily MenendezAdvanced Urothelial Carcinoma | September 15, 2023
The positive results were consistent with findings from the primary analysis, such as PFS and overall response benefit.
Zachary BessetteAdvanced Urothelial Carcinoma | August 30, 2023
Multiple genitourinary oncology therapies are in the spotlight this week, with new US FDA indications on the horizon.
Emily MenendezAdvanced Urothelial Carcinoma | August 29, 2023
Somatic alterations in DDR genes are common in patients with advanced urothelial cancer.
Shilpa Gupta, MDASCO 2023 | August 4, 2023
Drs. Shilpa Gupta and Vadim Koshkin continue on the EV-103 trial with reference to outcomes and toxicities in cohort K.
Shilpa Gupta, MDASCO 2023 | August 4, 2023
Drs. Shilpa Gupta and Vadim Koshkin discuss the EV-103 trial and data, including long-term results for cohort A.
Emily MenendezAdvanced Urothelial Carcinoma | August 2, 2023
Enfortumab vedotin and pembrolizumab have shown a survival benefit as individual treatments in locally advanced and mUC.
Tanya JindalASCO 2023 | July 28, 2023
Tanya Jindal expands upon the UNITE study findings relative to biomarkers of response for SG and EV for advanced UC.
Emily MenendezAdvanced Urothelial Carcinoma | July 13, 2023
Nivolumab and cisplatin-based chemotherapy administered before nivolumab alone demonstrates significant OS and PFS benefit.
Yohann Loriot, MD, PhDASCO 2023 | June 16, 2023
Drs. Loriot, Koshkin summarize erdafitinib versus chemotherapy in patients with advanced UC with select FGFR alterations.
Thomas Powles, MBBS, MRCP, MDASCO 2023 | June 15, 2023
Drs. Powles and Koshkin break down the Q-TWiST analysis conducted on the JAVELIN Bladder 100 study for advanced UC.
Seth Lerner, MD, FACSASCO 2023 | June 15, 2023
Drs. Lerner and Koshkin explain the implications of the latest data from the SWOG S1011 study for mUC.
Terence Friedlander, MDASCO 2023 | June 15, 2023
Drs. Friedlander and Koshkin highlight the 18-month data from the EV-103 study on EV/pembro first-line mUC treatment.
Arlene O. Siefker-Radtke, MDASCO 2023 | June 15, 2023
Drs. Siefker-Radtke and Koshkin detail the NORSE study design, results, and implications for treating patients with mUC.
Zachary BessetteASCO 2023 | June 2, 2023
A post hoc analysis of the IMvigor130 trial examined OS outcomes during first-line induction for patients with mUC.
Emily MenendezASCO 2023 | June 1, 2023
A post hoc exploratory analysis of the KEYNOTE-361 study was presented at the 2023 ASCO annual meeting.
Arnab Basu, MD, MPH, FACPAdvanced Urothelial Carcinoma | June 1, 2023
Drs. Koshkin and Basu comment on the best available treatment approach for patients with ctDNA-positive MIBC after surgery.
Arnab Basu, MD, MPH, FACPAdvanced Urothelial Carcinoma | June 1, 2023
Drs. Koshkin, Basu break down treatment considerations based on ctDNA status after radical cystectomy, among other factors.
Advertisement
Advertisement
Advertisement